News|Articles|March 4, 2024

Pharma Pulse 3/4/24: Short Sleep Duration May Reduce Lifespan, Path from Chatbots to A.G.I., and Local Pharmacies on the Brink

The latest news for pharma industry insiders.

Capturing and Keeping Gen-Z's Attention

In this Pharmaceutical Executive video interview, Ian Baer, Founder and Chief Soothsayer, Sooth, discusses how pharmaceutical companies and healthcare advertising agencies can adapt their strategies to attract Gen-Z.

Short Sleep Duration May Reduce Lifespan, Study Shows

Short sleep duration may be a causal risk factor for short lifespan, according to the authors of a recent study published in Translational Psychiatry. While insomnia was not shown to have a causal effect on lifespan, it can still have negative long-term effects on physical and mental health.

Path from Chatbots to A.G.I.

Demis Hassabis, the head of Google’s artificial intelligence division, talks about Google’s latest A.I. models, Gemini and Gemma; the existential risks of artificial intelligence; his timelines for artificial general intelligence; and what he thinks the world will look like post-A.G.I.

Local Pharmacies on the Brink, New Survey Reveals

As rumors swirl in Washington, D.C., that lawmakers may once again be punting on PBM reform, the National Community Pharmacists Association recently released a survey showing many local pharmacies are running out of time.

From @IQVIA_Institute on X:

Originally sanctioned for diabetes management as Ozempic, semaglutide's pivot toward weight loss promotion as Wegovy resulted in a surge in purchases and increased the IOP market share. Read more in IQVIA Institute’s report: https://bit.ly/49Rar0j. #Pharma

Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs.


Related to this article

Pharmaceutical Executive Daily
FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz on a hemophilia A biosimilar, and Joe Cunningham argues that executive drug-pricing deals alone won't fix costs.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance. dismisses the pharmaceutical industry's innovation argument against MFN pricing.